ANGIOTECH Trademark

Trademark Overview

On Thursday, August 9, 2001, a trademark application was filed for ANGIOTECH with the United States Patent and Trademark Office. The USPTO has given the ANGIOTECH trademark a serial number of 78078547. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 2, 2012. This trademark is owned by Angiotech Pharmaceuticals, Inc.. The ANGIOTECH trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceuticals, namely, therapeutic agents for the treatment of angiogenesis-related diseases, multiple sclerosis, psoriasis, arthritis

General Information

Serial Number78078547
Word MarkANGIOTECH
Filing DateThursday, August 9, 2001
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 2, 2012
Registration Number2978144
Registration DateTuesday, July 26, 2005
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, January 1, 2002

Trademark Statements

Goods and Servicespharmaceuticals, namely, therapeutic agents for the treatment of angiogenesis-related diseases, multiple sclerosis, psoriasis, arthritis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 2, 2012
Primary Code005
First Use Anywhere DateWednesday, October 7, 1998
First Use In Commerce DateWednesday, October 7, 1998

Trademark Owner History

Party NameAngiotech Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressVancouver, British Columbia V6A 1B6
CA
Party NameAngiotech Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressVancouver, British Columbia V6A 1B6
CA
Party NameAngiotech Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressVancouver, British Columbia V6T 1Z4
CA

Trademark Events

Event DateEvent Description
Friday, March 2, 2012CANCELLED SEC. 8 (6-YR)
Tuesday, October 24, 2006TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 26, 2005REGISTERED-PRINCIPAL REGISTER
Tuesday, May 10, 2005LAW OFFICE REGISTRATION REVIEW COMPLETED
Friday, May 6, 2005ASSIGNED TO LIE
Tuesday, May 3, 2005ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Monday, May 2, 2005STATEMENT OF USE PROCESSING COMPLETE
Friday, March 11, 2005USE AMENDMENT FILED
Friday, March 11, 2005TEAS STATEMENT OF USE RECEIVED
Monday, October 4, 2004EXTENSION 5 GRANTED
Friday, September 24, 2004EXTENSION 5 FILED
Friday, September 24, 2004TEAS EXTENSION RECEIVED
Monday, July 26, 2004CASE FILE IN TICRS
Thursday, February 19, 2004EXTENSION 4 GRANTED
Wednesday, February 4, 2004EXTENSION 4 FILED
Wednesday, February 4, 2004TEAS EXTENSION RECEIVED
Tuesday, October 14, 2003TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 3, 2003EXTENSION 3 GRANTED
Thursday, September 25, 2003EXTENSION 3 FILED
Thursday, September 25, 2003TEAS EXTENSION RECEIVED
Thursday, May 22, 2003TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 15, 2003EXTENSION 2 GRANTED
Wednesday, March 26, 2003EXTENSION 2 FILED
Wednesday, March 26, 2003TEAS EXTENSION RECEIVED
Friday, October 25, 2002EXTENSION 1 GRANTED
Thursday, September 26, 2002EXTENSION 1 FILED
Thursday, September 26, 2002TEAS EXTENSION RECEIVED
Tuesday, March 26, 2002NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 1, 2002PUBLISHED FOR OPPOSITION
Wednesday, December 12, 2001NOTICE OF PUBLICATION
Friday, October 26, 2001APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, October 15, 2001EXAMINERS AMENDMENT MAILED
Monday, October 1, 2001NON-FINAL ACTION MAILED
Tuesday, September 18, 2001ASSIGNED TO EXAMINER

Related Keywords

angiotech multiple diseases sclerosis psoriasis arthritis related angiogenesis namely therapeutic agents